Supreme Court Keeps Abortion Pill Access Available Nationwide

The United States Supreme Court recently made a significant decision regarding the availability of mifepristone, a medication used for abortion. According to The Guardian, the court ruled that the drug can continue to be sent through the mail and prescribed via telehealth—a system where patients talk to doctors online or by phone instead of visiting them in person. This decision stops a lower court’s ruling that would have banned the mailing of the drug across the entire country.

This legal battle started when the state of Louisiana sued the U.S. Food and Drug Administration (FDA). The state argued that the FDA’s rules for prescribing the drug made it difficult for Louisiana to enforce its own local ban on abortion. According to STAT News, Louisiana claimed that the federal policy undermined its state law and questioned the safety of the medication. However, the Supreme Court found that Louisiana did not have the legal standing—the right to bring a lawsuit to court—to challenge these federal rules. As a result, the case was sent back to a lower court for further review.

This is not the first time the court has faced this issue. In 2024, the Supreme Court heard a similar case brought by anti-abortion groups. At that time, the court decided that those groups did not have the standing to sue because they could not prove they were personally harmed by the FDA’s rules. The current case, however, remains active. According to NPR, access to the medication is likely to remain unchanged at least until next year while the case moves through the legal system.

Medication abortion is currently the most common way to end a pregnancy in the United States, accounting for nearly two-thirds of all abortions. Since the Supreme Court overturned the national right to abortion in 2022, many states have introduced their own bans. Despite these restrictions, the total number of abortions in the country has remained steady, largely because of the availability of mail-order medication. Research over many years has shown that these medications are safe and effective, according to reports from The Guardian.

Not all justices agreed with the decision to keep the drug available. Two justices, Clarence Thomas and Samuel Alito, dissented—meaning they disagreed with the majority. Justice Alito argued that the court’s decision was unreasoned and claimed it was part of a plan to weaken the 2022 ruling that removed the federal right to abortion. Justice Thomas suggested that mailing the drug should be considered a criminal act, pointing to an old law from 1873 called the Comstock Act, which was designed to stop the mailing of materials considered obscene.

The case has drawn attention from many different groups. Pharmaceutical companies and medical organizations have warned that if the court limits the FDA’s power to approve and regulate drugs, it could create major problems for the entire medical system. According to NPR, a group of former FDA leaders argued that the agency’s process for approving drugs is the gold standard for science-based decision-making. They believe that changing these rules based on legal challenges rather than scientific evidence would be dangerous.

Meanwhile, the political environment surrounding this issue remains tense. According to STAT News, some anti-abortion groups have been unhappy with the pace of the FDA’s review of mifepristone. This pressure recently led to the resignation of the FDA commissioner, Marty Makary, after he faced months of criticism from political allies of President Donald Trump. While the legal fight continues, the current ruling provides a temporary victory for those who support access to the medication.

Looking ahead, the case is expected to return to the Supreme Court through an official appeal in the future. For now, the status quo remains, meaning that patients across the country can still access mifepristone through telehealth and mail-order services. The outcome of this case will likely have long-term effects on how medication is regulated in the United States and how much power individual states have to challenge federal health policies.